ERYtech Pharma To Report Positive Initial Results On The Use Of GRASPA® In ALL Patients Allergic To E. Coli And Erwinia Derived Asparaginases At American Society of Hematology

Regulatory News: ERYTECH (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical need, announces the presentation of four case studies with GRASPA® in an expanded access program at the 56th Annual Meeting of the American Society of Hematology (ASH), December 6-9, 2014, in San Francisco, CA.

Help employers find you! Check out all the jobs and post your resume.